[1] Stanaway JD,Flaxman AD,Naghavi M,et al.The global burden of viral hepatitis from 1990 to 2013:findings from the Global Burden of Disease Study 2013. Lancet,2016,388(10):1081-1088.
[2] Liu J,Zhang S,Wang Q,et al.Seroepidemiology of hepatitis B virus infection in 2 million men aged 21 49 years in rural China:a population-based,cross-sectional study. Lancet Infect Dis,2015,16(1):80-86.
[3] Sui M,Wu R,Hu X,et al.Lowprevalence of hepatitis B virus infection in patients withautoimmune diseases in a Chinese patient population. J Viral Hepat,2014,21(12):925-929.
[4] Zhang E,Kosinska A,Lu M,et al.Current status of immunomodulatory therapy in chronic hepatitis B,fifty years after discovery of the virus:Search for the “magic bullet” to kill cccDNA. Antivir Res,2015,123(11):193-203.
[5] Sun J,Ma H,Xie Q,et al.Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B:A randomized controlled study. J Hepatol,2016,65(4):674-682.
[6] Gao B,Jeong WI,Tian Z.Liver:An organ with predominant innate immunity.Hepatology,2008,47(2):729-736.
[7] Yang Y,Han Q,Zhang C,et al.Hepatitis B virus antigens impair NK cell function. Int Immunopharmacol,2016,38(9):291-297.
[8] Zhang Z,Zhang S,Zou Z,et al.Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients. Hepatology,2011,53(1):73-85.
[9] Boni C,Lampertico P,Talamona L,et al.Natural killer cell phenotype modulation and natural killer/T-cell interplay in nucleos(t)ide analogue-treated hepatitis e antigen-negative patients with chronic hepatitis B. Hepatology,2015,62(6):1697-709.
[10] Bruder Costa J,Leroy V,Bouvier-Alias M,et al.Pegylated interferon α-2a triggers NK-cell functionality and specific T-Cell responses in patients with chronic HBV infection without HBsAg seroconversion. PLoS One,2016,11(6):1-20.
[11] Marcellin P,Ahn S H,Ma X,et al.Combination of tenofovir disoproxil fumarate and peginterferon INF-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology,2016,150(1):134-144.
[12] Stelma F,De N A,Tempelmans Plat-Sinnige MJ,et al. NK cell characteristics in chronic hepatitis B patients are associated with HBsAg loss after combination treatment with Peg-interferon alpha-2a and adefovir. J Infect Dis,2015,212(7):1042-1051.
[13] Kumar V.NKT-cell subsets:Promoters and protectors in inflammatory liver disease. J Hepatol,2013,59(3):618-620.
[14] Jiang X,Zhang M,Lai Q,et al.Restored circulating invariant NKT cells are associated with viral control in patients with chronic hepatitis B. Plos One,2011,6(12):69-75.
[15] Scroggins SM,Olivier AK,Meyerholz DK,et al.Characterization of regulatory dendritic cells that mitigate acute graft-versus-host disease in older mice following allogeneic bone marrow transplantation. Plos One,2013,8(9):274-283.
[16] Lin C,Zou H,Wang S.Hepatitis B e Antigen seroconversion is related with the function of dendritic cells in chronic Hepatitis B virus infection.Gastroenterol Res Pract,2014,20(14):413-418.
[17] Wei MJ,Pan XN,Wei KP,et al.Efficacy of HBV-pulsed DCs in combination with entecavir in patients with chronic hepatitis B infection. Int Immunopharmacol,2015,27(2):238-243.
[18] Boltjes A,Groothuismink ZM,van Oord GW,et al. Monocytes from chronic HBV patients react in vitro to HBsAg and TLR by producing cytokines irrespective of stage of disease. Plos One,2014,9(5):1-9.
[19] Dastjerdi MN,Momeni M,Bidaki R,et al.The effect of depression and anxiety on expression levels of toll like receptor signaling molecules in chronic HBV infected patients. Med J Islam Repub Iran,2015,29(5):841-849.
[20] Durantel D,Zoulim F,Durantel D,et al.Interplay between hepatitis B virus and TLR2-mediated innate immune responses:Can restoration of TLR2 functions be a new therapeutic option [J] Hepatol,2012,57(3):486-489.
[21] Wang S,Chen Z,Hu C,et al.Hepatitis B virus surface antigen selectively inhibits TLR2 ligand-induced IL-12 production in monocytes/macrophages by interfering with JNK activation.J Immunol,2013,190(10):5142-5151.
[22] Huang Z,Ge J,Pang J,et al.Aberrant expression and dysfunction of TLR2 and its soluble form in chronic HBV infection and its regulation by antiviral therapy. Antiviral Res,2015,118(6):10-19.
[23] Yan W,Wu D,Wang X,et al.Upregulation of NKG2C(+) natural killer cells,TLR-2 expression on monocytes and downregulation of regulatory T-cells influence PEG-IFN treatment efficacy in entecavir-suppressed patients with CHB. Antivir Ther,2015,20(6):591-602.
[24] Zoulim F,Luangsay S,Durantel D.Targeting innate immunity:A new step in the development of combination therapy for chronic hepatitis B. Gastroenterology,2013,144(7):1342-1344.
[25] Lanford R E,Guerra B,Chavez D,et al.GS-9620, an Oral agonist of toll-like receptor-7,induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology,2013,144(7):1508-1517.
[26] Chung RT,Roberts LR,Bisceglie A,et al.HBV-specific and global T-cell dysfunction in chronic hepatitis B. Gastroenterology,2015,150(3):684-695.
[27] Piao RL,Liu YY,Tian D,et al.Adefovir dipivoxil modulates cytokine expression in Th1/Th2 cells in,patients with chronic hepatitis B. Mol Med Rep,2012,5(1):184-189.
[28] Sprinzl M F,Russo C,Kittner J,et al.Hepatitis B virus-specific T-cell responses during IFN administration in a small cohort of chronic hepatitis B patients under nucleos(t)ide analogue treatment. J Viral Hepat,2014,21(9):633-641.
[29] Tian ZF,You ZL,Yi H,et al.Effect of entecavir on CD4+ T-cell subpopulations in patients with chronic hepatitis B. Ann Hepatol,2016,15(2):174-182.
[30] You J,Yan YZ,Sriplung H,et al.Decline of hepatitis B virus load correlate with increase of Th1/Th2 immunity in chronic hepatitis B patients during long-term treatment with entecavir.Int J Infect Dis,2014,21(4):320.
[31] Staron M,Gray S,Marshall H,et al.The transcription factor foxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8+,T Cells during chronic infection. Immunity,2014,41(5):802-814.
[32] Rong F,Jian S,Quan Y,et al.Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. Gut,2016,65(2):313-320.
[33] Tang Y,Chen X,Zhang Y,et al.Fusion protein of tapasin and hepatitis B core antigen 18 27 enhances T helper cell type 1/2 cytokine ratio and antiviral immunity by inhibiting suppressors of cytokine signaling family members 1/3 in hepatitis B virus transgenic mice. Mol Med Rep,2014,9(4):1171-1178.
[34] Wang GQ,Ding YP,Dong YH.Telbivudine treatment is associated with high hepatitis B e antigen seroconversion and immune modulatory effects in chronic hepatitis B patients. J Viral Hepat,2013,20(4):9-17.
[35] Chokshi S,Cooksley H,Riva A,et al.Identification of serum cytokine profiles associated with HBeAg seroconversion following antiviral treatment interruption.Viral Immunol,2014,27(5):235-244.
[36] Manigold T,Racanelli V.T-cell regulation by CD4 regulatory T cells during hepatitis B and C virus infections:facts and controversies. Lancet Infect Dis,2008,7(12):804-813.
[37] Shen C,Yan WZ,Zhao CY,et al.Increased CD4+CD25+,regulatory T cells correlate with poor short-term outcomes in hepatitis B virus-related acute-on-chronic liver failure patients. J Microbiol Immunol Infect,2015,48(2):137-146.
[38] Yang J,Ping Y,Li W,et al.Phenotypes and clinical significance of circulating CD4+CD25+,regulatory T cells (Tregs) in patients with acute-on-chronic liver failure(ACLF). J Transl Med,2012,10(1):284-292.
[39] Liu Y,Cheng LS,Wu SD,et al.IL-10-producing regulatory B cells suppressed effector T but enhanced regulatory T cells in chronic HBV infection. Clin Sci (Lond),2016,30(11):907-919.
[40] Yang J,Sheng G,Xiao D,et al.The frequency and skewed T-cell receptor beta-chain variable patterns of peripheral CD4+CD25+ regulatory T-cells are associated with hepatitis B e antigen seroconversion of chronic hepatitis B patients during antiviral treatment. Cell Mol Immunol,2016,13(5):678-687.
[41] Pavadm,Dushek O.Mechanisms for T cell receptor triggering.Nat Rev Immunol,2011,11(1):47-55.
[42] Fazilleau N,Mark L,Mcheyzer-Williams LJ,et al.Follicular hel-
per T cells:Lineage and location. Immunity,2009,30(3):324-335.
[43] Li Y,Ma S,Tang L,et al.Circulating CXCR5(+) CD4(+) T cells benefit HBeAg seroconversion through IL-21 in patients with chronic HBV infection. Hepatology,2013,58(4):1277-1286.
[44] Hu T T,Song X F,Lei Y,et al.Expansion of circulating TFH cells and their associated molecules: involvement in the immune landscape in patients with chronic HBV infection. Virol J,2013,11(1):1-9.
[45] Zhang L,Zhang M,Li H,et al.TFH cell-mediated humoral immune response and HBsAg level can predict HBeAg seroconversion in chronic hepatitis B patients receiving peginterferon-IFN2αtherapy.Mol Immunol,2016, 73(5):37-45.
[46] Lei Y,Hu T,Song X,et al.Production of autoantibodies in chronic hepatitis B virus infection is associated with the augmented function of blood CXCR5+CD4+T Cells. PLoS One,2016,11(9):1-9. |
